

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [ID3970]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No potential equality issues have been identified during the scoping process.
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/A
3. Has any change to the draft scope been agreed to highlight potential equality issues?
No changes were made to the draft scope to highlight any potential equality issues.
4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No potential equality issues have been identified during the scoping process.

Approved by Associate Director (name): Ross Dent
Date: 22/11/2022